Atara Biotherapeutics, Inc. (ATRA) Form 8-K — Jun 26, 2026
Atara Biotherapeutics notified Chief Accounting Officer Yanina Grant-Huerta that her employment will end effective July 17, 2026. To fill the leadership gap, the Board appointed Kevin G. Sarney as interim Chief Financial Officer effective June 26, 2026. Mr.
Price after filing
1 day: 0.0%7 days: +14.0%30 days: -20.1%
Close on the filing date to close N calendar days later (from $10.22). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.